Driving the discussion about the greater propensity for doing better with neoadjuvant chemotherapy for non-small cell lung cancer

Abigail K. Zamora, Anthony W. Kim


One of the most challenging aspects of care in non-small cell lung cancer (NSCLC) is determining the optimal multimodal strategy to fight advanced disease at the time of presentation. The barrage of chemotherapy, radiation, surgery, and now immunotherapy may be beginning to mitigate the impact of locoregionally advanced disease on patient outcomes in NSCLC.